Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment

The BCL-2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL-2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Chen, Xufeng, Glytsou, Christina, Zhou, Hua, Narang, Sonali, Reyna, Denis E., Lopez, Andrea, Sakellaropoulos, Theodore, Gong, Yixiao, Kloetgen, Andreas, Yap, Yoon Sing, Wang, Eric, Gavathiotis, Evripidis, Tsirigos, Aristotelis, Tibes, Raoul, Aifantis, Iannis
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606342/
https://ncbi.nlm.nih.gov/pubmed/31048321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0117
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge